AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Dialybrid secures €15 million in a Series A round led by XGEN Venture to fund the development of its Silkothane® Arteriovenous Graft for hemodialysis.
Dialybrid S.r.l. has closed a €15 million Series A round aimed at advancing its innovative Silkothane® Arteriovenous Graft for vascular access in hemodialysis. Led by XGEN Venture, with participation from CDP Venture Capital, this funding will support both clinical and preclinical developments. The first-in-human clinical trial has commenced successfully
Company Information
Company
Dialybrid
Location
Lombardy, Italy
About
Dialybrid S.r.l. is a privately held medical device company developing a novel vascular access solution for hemodialysis based on Silkothane®, a patented hybrid material made up of silk fibroin and polyurethane. The company focuses on addressing unmet clinical needs in vascular access for hemodialysis with innovative solutions. Their Silkothane® Arteriovenous Graft aims to improve patient outcomes and redefine standards of care. Dialybrid is advancing its product through clinical trials for regulatory approval.
Fundz sees it the moment Dialybrid raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LombardyBiotechnologyHealth CareMedicalMedical Device